LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Home・Aktien・Merck & Co Inc.

Merck & Co Inc.

Geschlossen

Branche Gesundheitswesen

103.73 -0.47

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

103.7

Max

105.05

Schlüsselkennzahlen
By Trading Economics
Einkommen	693M 5.5B
Verkäufe	310M 16B
KGV Branchendurchschnitt	137.56 112.16
EPS	2.28
Gewinnspanne	33.861
Angestellte	72,000
EBITDA	491M 7.4B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+31.51 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	31. Okt. 2024
Nächste Dividendenausschüttung	6. Jan. 2025
Nächstes Ex-Dividendendatum	12. Dez. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-9.4B 278B
Vorheriger Eröffnungskurs	104.2
Vorheriger Schlusskurs	103.73

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

103.86 / 109.69 Unterstützung & Widerstand

Merck & Co Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Okt. 2024, 14:04 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences

9. Aug. 2024, 11:14 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Buying Drug Targeting B-Cell Diseases for Up to $1.3 Billion

30. Juli 2024, 14:00 UTC

Ergebnisse

Trending: Merck 2Q Profit Beats Expectations; Fiscal Year Adjusted EPS Outlook Lowered

30. Juli 2024, 11:17 UTC

Ergebnisse

Merck Swings to 2Q Profit Ahead of Views, Lowers FY24 Adjusted EPS Outlook

24. Okt. 2024, 13:50 UTC

Akquisitionen, Fusionen, Übernahmen

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

3. Okt. 2024, 19:02 UTC

Akquisitionen, Fusionen, Übernahmen

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

3. Okt. 2024, 18:20 UTC

Akquisitionen, Fusionen, Übernahmen

CEOs Are on the Hunt for More M&A. Where the Next Deals Are. -- Barrons.com

1. Okt. 2024, 10:46 UTC

Akquisitionen, Fusionen, Übernahmen

Merck to Post 3Q Charge of About 28c/Share on Curon Deal >MRK

1. Okt. 2024, 10:46 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, From Curon Biopharmaceutical

30. Sept. 2024, 21:02 UTC

Top News

FOMO on China Stock Rally? Think Twice About Buying In. -- Barrons.com

12. Sept. 2024, 15:02 UTC

Top News

Moderna Cost Cuts Fail to Restore Investor Trust -- Heard on the Street -- WSJ

12. Sept. 2024, 10:00 UTC

Top News

Moderna Pulls Back on R&D and Delays Timeline for Profitability -- Barrons.com

9. Sept. 2024, 17:55 UTC

Top News

A Better Drug Than Merck's Blockbuster Keytruda? Not So Fast -- WSJ

9. Sept. 2024, 09:17 UTC

Top News

Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial -- Barrons.com

3. Sept. 2024, 17:22 UTC

Top News

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

12. Aug. 2024, 14:30 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12. Aug. 2024, 09:30 UTC

Top News

Akquisitionen, Fusionen, Übernahmen

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1. Aug. 2024, 15:56 UTC

Ergebnisse

Merck Created the World's Biggest Drug. Now It -2-

1. Aug. 2024, 15:56 UTC

Ergebnisse

Merck Created the World's Biggest Drug. Now It Has to Replace It. -- Barrons.com

30. Juli 2024, 15:53 UTC

Ergebnisse

Nasdaq Dives As Microsoft Earnings Loom; Two Dow Jones Leaders Crater On Earnings (Live Updates) -- IBD

30. Juli 2024, 15:28 UTC

Market Talk

Ergebnisse

Merck's Keytruda Continues to See Growth in U.S., Abroad -- Market Talk

30. Juli 2024, 13:45 UTC

Ergebnisse

Trending: Merck 2Q Profit Beats Expectations; FY Adj EPS Outlook Lowered

30. Juli 2024, 10:45 UTC

Ergebnisse

Merck Beats Profit And Sales Expectations Amid Keytruda Strength, But Provides Mixed Full-Year Outlook -- MarketWatch

30. Juli 2024, 10:32 UTC

Ergebnisse

Merck Revised 2024 Adjusted EPS View Includes 51c/Share Charge on EyeBio Deal >MRK

30. Juli 2024, 10:31 UTC

Ergebnisse

Merck 2Q Sales Rose 11% Ex-Forex >MRK

30. Juli 2024, 10:31 UTC

Ergebnisse

Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short -- IBD

30. Juli 2024, 10:30 UTC

Ergebnisse

Merck 2Q Keytruda Sales Up 16% >MRK

30. Juli 2024, 10:30 UTC

Ergebnisse

Merck 2Q Pharmaceutical Sales $14.41B >MRK

30. Juli 2024, 10:30 UTC

Ergebnisse

Merck 2Q Keytruda Sales $7.27B >MRK

30. Juli 2024, 10:30 UTC

Ergebnisse

Merck 2Q Gardasil/Gardasil 9 Sales Up 1% >MRK

Peer-Vergleich

Kursveränderung

Merck & Co Inc. Prognose

Kursziel

By TipRanks

31.51% Vorteil

12-Monats-Prognose

Durchschnitt 137.07 USD 31.51%

Hoch 155 USD

Tief 115 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck & Co Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

Buy

Halten

Sell

Basierend auf 20 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Merck & Co Inc. – Dist abgegeben haben.

Technischer Score

By Trading Central

103.86 / 109.69Unterstützung & Widerstand

All events are bearish.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Merck & Co Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.